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Background: An increasing number of HIV-positive individuals
now start antiretroviral therapy (ART) with high CD4 cell counts.
We investigated whether this makes restoration of CD4 and CD8 cell
counts and the CD4:CD8 ratio during virologically suppressive ART
to median levels seen in HIV-uninfected individuals more likely and
whether restoration depends on gender, age, and other
individual characteristics.
Methods: We determined median and quartile reference values
for CD4 and CD8 cell counts and their ratio using cross-sectional
data from 2309 HIV-negative individuals. We used longitudinal
measurements of 60,997 HIV-positive individuals from the
Antiretroviral Therapy Cohort Collaboration in linear mixed-
effects models.
Results: When baseline CD4 cell counts were higher, higher long-
term CD4 cell counts and CD4:CD8 ratios were reached. Highest
long-term CD4 cell counts were observed in middle-aged individ-
uals. During the ﬁrst 2 years, median CD8 cell counts converged
toward median reference values. However, changes were small
thereafter and long-term CD8 cell count levels were higher than
median reference values. Median 8-year CD8 cell counts were higher
when ART was started with ,250 CD4 cells/mm3. Median
CD4:CD8 trajectories did not reach median reference values, even
when ART was started at 500 cells/mm3.
Discussion: Starting ART with a CD4 cell count of $500 cells/
mm3 makes reaching median reference CD4 cell counts more
likely. However, median CD4:CD8 ratio trajectories remained
below the median levels of HIV-negative individuals because of
persisting high CD8 cell counts. To what extent these subnormal
immunological responses affect speciﬁc clinical endpoints re-
quires further investigation.
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INTRODUCTION
Since 2012, US Guidelines have recommended offering
antiretroviral therapy (ART) to all individuals diagnosed with
HIV, regardless of their CD4 cell count.1 As a result, an
increasing number of HIV-1–positive individuals start ART at
high CD4 cell counts. Furthermore, of those starting ART,
a considerable proportion does so at a relatively old age. For
example, in the Netherlands in 2015, 37% of those starting
ART did so with a CD4 count of$500 cells/mm3 and 23% of
individuals newly diagnosed with HIV were aged 50 years or
older.2 Generally, the increase in CD4 cell count during
virologically suppressive ART is less in older individuals.3–9
This diminished recovery of CD4 cell count among older
individuals has been attributed to lower thymic function.10,11
Lower CD4 counts with older age are also seen in
healthy European HIV-negative populations, although the
decrease seems to occur mainly at a very advanced age.12–16
CD4 cell counts have also been reported to differ according to
smoking status,17 gender,13 the time of day of sampling,18
season,19 and region of origin.20,21
Although CD4 cell count is considered the key
prognostic factor for AIDS morbidity and mortality, some
evidence suggests that the CD4:CD8 ratio also independently
predicts time to death and non–AIDS-deﬁning endpoints.22–24
In the general population, a CD4:CD8 ratio ,1.0 is
associated with mortality in very elderly people.25 In HIV-
positive individuals, the ratio is decreased and low ratios are
associated with pathological changes in the immune system
such as immune activation, exhaustion, senescence, and
memory abnormalities.26–28 The ratio increases rapidly during
the ﬁrst few years on ART and keeps increasing up to 15
years after starting ART, albeit slowly,29 and the ratio does
not reach levels higher than 1.0 in two-thirds of individuals
despite long-term viral suppression.30,31
We studied whether an early start, at high CD4 cell
counts followed by long-term virologically suppressive ART,
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makes restoration to levels of CD4 and CD8 cell counts and
the CD4:CD8 ratio seen in HIV-negative individuals more
likely. We also investigated the effect of age and other factors
on these immunological changes.
METHODS
HIV-Negative Study Participants
To obtain reference values, we used 2309 cross-
sectional CD4 and CD8 cell counts and CD4:CD8 ratios
obtained from HIV-negative individuals recruited from the
background population to the Danish HIV cohort (either
healthy staff or blood and stem-cell donors) and HIV-negative
individuals from the Dutch AGEhIV cohort (recruited either
at the STI clinic of the Amsterdam Public Health Service or
the existing Amsterdam Cohort Studies on HIV/AIDS). CD4
and CD8 cell counts and CD4:CD8 ratios were used as
dependent variables in 3 linear regression models including
age and gender and their interaction as independent variables.
We used the 25th, 50th, and 75th prediction percentiles as the
lower, median, and upper reference values, respectively, in
graphs to put the immunological restoration during virolog-
ically suppressive ART in HIV-positive individuals into
context (see Text File SDC 1, Supplemental Digital Content,
http://links.lww.com/QAI/B244 for further details on the
selection and analysis of CD4 and CD8 cell counts and the
CD4:CD8 ratio in HIV-negative individuals).
HIV-Positive Study Participants
We used data from the Antiretroviral Therapy Cohort
Collaboration (ART-CC; http://www.art-cohort-collaboration.
org), an international collaboration of 21 cohort studies from
Europe and North America that was established in 2000 to
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examine the prognosis of HIV-1–positive, treatment-naive
individuals initiating ART, a combination of at least 3
antiretroviral drugs.32 Participation of cohorts has been
approved by their ethics committees or institutional review
boards according to local regulations (see Text File SDC 2,
Supplemental Digital Content, http://links.lww.com/QAI/B244
for a list of participating cohorts). We only included individuals
who were 18 years of age or older and had a CD4 cell count
and viral load measured at the start of ART. All included
individuals had a decrease in HIV RNA viral load to below
400 copies per milliliter within 9 months from start of ART. In
sensitivity analyses, we changed the time limit to 6 months and
cutoff to 50 copies per milliliter.
Outcome
We modeled longitudinal CD4 and CD8 cell counts and
CD4:CD8 ratios after the start of ART. We excluded follow-
up after an ART interruption longer than 2 weeks and after
the ﬁrst of 2 consecutive plasma viral load measurements
$400 copies per milliliter. In sensitivity analyses, we only
included measurements until an ART interruption longer than
1 week or until the ﬁrst plasma viral load measurement $400
copies per milliliter. Models including CD8 cell counts or
CD4:CD8 ratios only included participants from the 14
cohorts that had collected data on these variables.
Statistical Methods
Trends in CD4 and CD8 cell counts and their ratio were
modeled using linear mixed-effects models (lme4 package33
in R version 3.0.334). CD4 cell counts were found to best
comply with normality assumptions when square root trans-
formed, CD8 cell counts when log transformed, and the
CD4:CD8 ratio when ﬁfth root transformed. The trends over
time since start of ART were modeled using restricted cubic
splines with knots at 0, 0.1, 0.25, 0.5, 3, and 7.5 years. We
used a random intercept and 2 random slopes (one slope
between 0 and 6 months and one slope from 6 months
onward, with an unstructured covariance matrix) per individ-
ual as well as a random intercept for cohort.
All models included gender, region of birth (Europe/
North America, Caribbean/South America, sub-Saharan Afri-
ca, and other regions), transmission risk group [men who
have sex with men (MSM), injecting drug use (IDU),
heterosexual, other, and unknown], age, CD4 cell count,
and HIV RNA at the start of ART (measurement closest to the
start of ART in the period 90 days before to 6 days after
TABLE 1. Demographical and Clinical Characteristics at the
Start of ART
N %
Total 60,997 100.0
Gender
Men 46,076 75.5
Women 14,921 24.5
Transmission risk group
MSM 24,591 40.3
IDU 4685 7.7
Heterosexual contact 23,335 38.3
Other/Unknown 8386 13.7
Age at start of ART (yr), median, IQR 39, 32–46
16–29 10,796 17.7
30–39 21,796 35.7
40–49 17,798 29.2
$50 10,607 17.4
Region of birth
Europe/North America 44,717 73.3
Caribbean/South America 3569 5.9
Sub-Saharan Africa 7729 12.7
Other/unknown 4982 8.2
Year of start of ART (median, IQR) 2007, 2004–2009
2001–2003 12,765 20.9
2004–2006 14,827 24.3
2007–2009 19,231 31.5
2010–2012 14,174 23.2
CD4 cell count at start of ART (cells/mm3),
median, IQR
246, 130–350
0–49 7301 12.0
50–99 4838 7.9
100–199 11,263 18.5
200–349 22,206 36.4
350–499 9575 15.7
$500 5814 9.5
HIV RNA at start of ART (copies per
milliliter), median, IQR
64,500, 14,300–
182,800
,10,000 12,963 21.2
10,000–100000 23,701 38.9
$100,000 24,333 39.9
Smoking status at the start of ART, missing in
1683/16,650* (10.1%)
Nonsmoker 8515 56.9
Current smoker 6452 43.1
Hepatitis C status at the start of ART, missing
in 2093/21,176* (9.9%)
HCV-negative 17,072 89.5
HCV-positive 2011 10.5
CMV status at the start of ART, missing in
1922/8418* (22.8%)
CMV-negative 740 11.4
CMV-positive 6496 88.6
*Total number of participants in the subset of cohorts used in the analysis.
TABLE 2. Median (IQR) CD8 Cell Count and CD4:CD8 Ratio
at the Start of ART for Different CD4 Categories
CD4 Cell Count at the
Start of ART (cells/
mm3) N
CD8 Cell Count,
Median, IQR
(cells/mm3)
CD4:CD8
Ratio, Median,
IQR
0–49 3914 392, 233–610 0.05, 0.03–0.09
50–99 2704 600, 402–890 0.11, 0.08–0.17
100–199 6860 757, 525–1070 0.20, 0.14–0.28
200–349 13,654 900, 650–1250 0.27, 0.19–0.37
350–499 6206 995, 717–1394 0.37, 0.26–0.52
$500 3967 1040, 753–1472 0.58, 0.41–0.79
Any CD4 cell count 37,305 830, 560–1195 0.21, 0.11–0.34
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starting ART). CD4 cell count trends were also allowed to
vary according to period of starting ART (2001–2003, 2004–
2006, 2007–2009, and 2010–2012).
Because data on smoking status, CD8 cell count, and
hepatitis C virus (HCV) and cytomegalovirus (CMV) co-
infection were not collected in all cohorts, we only used data
from cohorts with at least 85% complete data on smoking
status, CD8 cell count, and HCV coinfection. For CMV
coinfection, we used data from the 5 cohorts with available
data on CMV. Therefore, these variables were not evaluated
together in one model but in separate models (For more
detailed information on interaction terms and continuous
covariable modeling, see Text File SDC 3, Supplemental
Digital Content, http://links.lww.com/QAI/B244).
To help interpret, the ﬁtted values were backtrans-
formed to their original scale, where they can be considered
as median values. They are graphically displayed for selected
values of age and CD4 and CD8 cell counts at the start
of ART.
RESULTS
HIV-Negative Population
Median CD4 and CD8 cell count in HIV-negative
participants decreased with older age, whereas the median
CD4:CD8 ratio was higher with older age (see Figures A–C
SDC 4, Supplemental Digital Content, http://links.lww.com/
QAI/B244). For a 37-year-old man, the median CD4 cell
count was 830 cells/mm3 and 1005 CD4 cells/mm3 for
a woman. These values for the CD8 cell count and the
CD4:CD8 ratio were 499 cells/mm3 and 1.69 for men and 519
CD8 cells/mm3 and 1.98 for women, respectively. Modeling
age using splines (see Figures SDC 5–7, Supplemental Digital
Content, http://links.lww.com/QAI/B244) gave a better data
ﬁt than modeling age linearly, but because the resulting
trajectories were not consistently increasing or decreasing
with higher age, we chose to model age linearly.
HIV-Positive Population
The majority of 60,997 included HIV-positive individ-
uals was men (75%) and born in Europe/North America
(73%), as shown in Table 1. Forty percent were in the MSM
transmission risk group. Median age was 39 years [inter-
quartile range (IQR) 32–46]. Median CD4 cell count was 246
cells/mm3 (IQR 130–350). The median CD8 cell count in the
subset of 37,305 individuals included in the analysis of CD8
cell count and CD4:CD8 ratio was 830 cells/mm3 and the
median CD4:CD8 ratio was 0.21 (Table 2). Median CD8 cell
count and CD4:CD8 ratio were both lower when ART was
started at lower CD4 cell count.
CD4 Cell Count Trajectories
We used 599,445 CD4 cell count measurements. The
number of individuals with measurements after 2, 4, 6, and 8
years of virologically suppressive ART was 29,791 (49%),
16,679 (27%), 8836 (14%), and 4209 (7%), respectively. The
median observed CD4 cell count at 8 years for those starting
with a CD4 count of 0–49 (n = 728), 50–99 (n = 480), 100–
199 (n = 1025), 200–349 (n = 1359), 350–499 (n = 377), and
$500 cells/mm3 (n = 240) was 485, 507, 570, 667, 793, and
923 cells/mm3, respectively.
Higher CD4 cell count at the start of ART was associated
with higher median 8-year counts (Fig. 1). Only when ART was
started with a CD4 count of 500 cells/mm3, the median 8-year
CD4 cell count in men reached the median reference value. CD4
cell count was nonlinearly associated with age. Middle-aged men
showed higher median CD4 cell counts at 8 years compared to
older and younger men when ART was started with a CD4 count
FIGURE 1. Median CD4 cell count at 8
years of virologically suppressive ART (95%
confidence intervals in color) in men and
women by age at 8 years after the start of
ART. Trends are shown for specific baseline
CD4 cell counts of 100, 200, 350, and 500
cells/mm3. Curves are for an average refer-
ence heterosexual individual born in West-
ern Europe/North America starting ART
between 2004 and 2006 with a plasma viral
load of 4.81 log10 copies per milliliter and
random intercept and slopes equal to zero.
Dashed lines show the lower, normal and
upper reference CD4 cell counts by age as
estimated in HIV-negative men and women.
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of 350 or 500 cells/mm3. Women showed a similar but stronger
pattern. Among those starting at a CD4 count of 500 cells/mm3,
45-year-old reference men (911 cells/mm3, 95% conﬁdence
interval: 889–933) and 51-year-old women (971 cells/mm3, 95%
conﬁdence interval: 932–1011) reached highest median 8-year
CD4 cell counts. Trajectories of women aged 20 years at the start
of ART were initially higher than those of older women during
the ﬁrst 2 years of ART, but ﬂattened, whereas trajectories of
women aged 37, 54, or 70 years at baseline kept increasing (see
Figure SDC 8, Supplemental Digital Content, http://links.lww.
com/QAI/B244). Similar results were obtained when analyses
were restricted to those who reached ,50 HIV copies per
milliliter within 6 months from starting ART. CD4 cell count
trajectories were also similar according to the starting year of
ART (results not shown).
CD4 cell counts at 8 years were lower with increasing
baseline CD8 cell counts until 400 cells/mm3, but the relation
ﬂattened off beyond 400 cells/mm3 (see Figure SDC 9,
Supplemental Digital Content, http://links.lww.com/QAI/B244
in analysis additionally adjusted for baseline CD8 cell count in
a subset of 37,305 individuals with CD8 cell counts available).
CD8 Cell Count Trajectories
We used 374,985 CD8 cell count measurements from
37,305 individuals. The number of individuals with CD8 cell
counts during virologically suppressive ART after 2, 4, 6, and
8 years was 18,316 (49%), 10,310 (28%), 5480 (15%), and
2525 (7%), respectively. The median CD8 cell count at 8
years was 765 cells/mm3 (IQR 558–1040). For those starting
with 0–49 (410 individuals remaining in follow-up), 50–99 (n
= 281), 100–199 (n = 655), 200–349 (n = 794), 350–499 (n =
242), and $500 CD4 cells/mm3 (n = 143), the median 8-year
CD8 cell count was 800 (IQR 575–1100), 770 (566–1075),
774 (570–1006), 740 (540–1030), 751 (558–1050), and 810
(557–1072) cells/mm3, respectively.
Median CD8 cell counts at 8 years after the start of
ART showed a similar downward trend with higher age as the
trend observed in HIV-negatives (Fig. 2). This downward
trend was not observed in men and women younger than 40
years, and median 8-year CD8 cell counts were similar across
all ages below 40 years of age. Higher CD8 cell counts at the
start were associated with higher CD8 cell counts at 8 years.
Median 8-year CD8 counts were similar to median reference
values when ART was started with a CD8 cell count of 300
cells/mm3 and a CD4 cell count of 200, 350, or 500 cells/
mm3. Similar median CD8 cell counts at 8 years were reached
for those starting with a CD4 count of 200, 350, or 500 cells/
mm3. However, median 8-year CD8 cell counts were higher
when ART was started with a CD4 count of 50 cells/mm3.
The association between lower baseline CD4 cell counts and
higher CD8 cell counts at 8 years starts from CD4 cell counts
FIGURE 2. Median CD8 cell count after 8
years of virologically suppressive ART by age,
gender, and CD4 and CD8 cell counts at the
start of ART, for an average reference het-
erosexual individual born in Western Europe
or North America and starting ART with 4.81
log10 copies per milliliter and random inter-
cept and slopes equal to zero. Dashed lines
show the upper, normal, and lower refer-
ence CD8 cell count values.
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below approximately 250 cells/mm3 (see Figure SDC 10,
Supplemental Digital Content, http://links.lww.com/QAI/
B244).
Median CD8 cell count trajectories show a rapid
decline in CD8 cell count during the ﬁrst year when ART
was started with a CD8 count of 800 or 1200 cells/mm3 and
a more gradual decline after 1 year. CD8 cell counts remained
higher than the median reference range during the ﬁrst 8 years
(see Figure SDC 11, Supplemental Digital Content, http://
links.lww.com/QAI/B244).
CD4:CD8 Ratio Trajectories
Median CD4:CD8 ratio at 8 years was 0.81 (IQR 0.57–
1.11). The median 8-year ratio for those starting with 0–49,
50–99, 100–199, 200–349, 350–499, and $500 CD4 cell/
mm3 was 0.63 (IQR 0.45–0.85), 0.66 (0.47–0.87), 0.76
(0.54–1.01), 0.89 (0.64–1.19), 1.05 (0.75–1.38), and 1.09
(0.88–1.50) cells/mm3, respectively.
Figure 3 shows that higher median CD4:CD8 ratios
were reached when CD4 cell counts at the start of ART were
higher and CD8 cell counts were lower (ie, the ratio at the
start was higher). Among the combinations shown, median
reference values were only reached in men younger than 60
years (at 8 years) who had started ART with the combination
of a CD4 count of 500 cells/mm3 and CD8 count of 300 cells/
mm3. Men and women with a CD4 count of 350 or 500 cells/
mm3 at the start reached median CD4:CD8 ratios $1.0 at 8
years, irrespective of the CD8 cell count at the start, except in
men older than 60 years of age at 8 years.
Median CD4:CD8 ratio trajectories continued to
increase during the ﬁrst 8 years of ART (see Figure SDC
12, Supplemental Digital Content, http://links.lww.com/QAI/
B244). Ratio trajectories were higher in women compared
with men.
Association of Other Variables
With Trajectories
The association between region of origin, transmission
risk group, HIV RNA, smoking status, and HCV and CMV
coinfection at the start of ART and CD4 and CD8 cell count
and ratio trajectories and levels reached at 8 years is discussed
in text and shown in ﬁgures (see Figures SDC 13–15,
Supplemental Digital Content, http://links.lww.com/QAI/
B244 and Table SDC 16, Supplemental Digital Content,
http://links.lww.com/QAI/B244). In short, CD4 and CD8 cell
count after 8 years of virologically suppressive ART were
higher in smokers compared with nonsmokers. Median
trajectories of CD4 cell count and the CD4:CD8 ratio were
lower in individuals infected by IDU compared with non-
IDU. CMV-negative individuals showed a stronger decrease
in CD8 cell count in the ﬁrst year after starting ART
FIGURE 3. Median CD4:CD8 ratio at 8
years after the start of ART (95% confidence
intervals in color) according to age at 8
years after the start of ART, gender, and
CD4 and CD8 cell counts at the start of ART.
Median ratios shown are those for an aver-
age reference individual in the heterosexual
transmission risk group, born in Europe/
North America, aged 37 years at the start of
ART, and a plasma viral load of 4.81 log10
copies per milliliter at the start of ART and
random intercept and slopes equal to zero.
Dashed lines show the upper, normal and
lower reference CD4:CD8 ratio in HIV-neg-
ative men and women.
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compared with CMV-positive individuals, and because CD4
cell count trajectories were fairly similar, CD4:CD8 ratio
trajectories in CMV-positive individuals were lower com-
pared with those in CMV-negative individuals.
DISCUSSION
As ART is now both recommended and often started at
high CD4 cell counts, we investigated whether median
trajectories of CD4 and CD8 cell count and the CD4:CD8
ratio reach median reference values when ART is started with
high (eg, 500 cells/mm3) and lower CD4 cell counts (such as
350, 200, and 50 cells/mm3). During 8 years of virologically
suppressive ART, median reference CD4 cell counts (about
800 cells/mm3) were reached only by men starting at high
CD4 cell counts $500 cells/mm3. Despite virologically
suppressive ART, CD8 cell count trajectories converged after
2 years to a stable level above the median reference value.
Median reference CD8 cell counts were only reached when
ART was started at low CD8 cell count (such as 300 cells/
mm3). As a result of persisting high CD8 cell counts, median
reference CD4:CD8 ratios were not reached, even when ART
was started at high CD4 cell counts.
Measurements after interruption of ART of more than 2
weeks and after a conﬁrmed HIV RNA .400 copies per
milliliter were not included in the analysis. Our results are,
therefore, not generalizable to all individuals who start ART
but rather provide an estimate of the maximum capacity of the
immune system to restore CD4 and CD8 cell counts and their
ratio during long-term virologically suppressive ART. Our
selection of individuals, therefore, will also include some
immunological nonresponders, individuals with nonperfect
adherence, women during pregnancy, and individuals with
certain comorbidities or comedication that may impact CD4
and CD8 cell count trajectories. Furthermore, generalizability
may be slightly impaired if those that interrupt ART or with
virological failure have different CD4 or CD8 cell count
trajectories before interruption or failure.
Median reference CD4 cell counts were only reached
within 8 years in more than 50% of men when ART was
started with high CD4 cell counts (such as 500 cells/mm3). By
deﬁnition, approximately 50% of individuals will have had
a pre–HIV-infection CD4 cell count below the population
median, and some even below 500 cells/mm3. Hence, those
who start ART with a CD4 count more than 500 cells/mm3
are already a selected subgroup that probably had pre-HIV
CD4 counts above the population median. Likewise, those
who had lower-than-average CD4 counts before they
acquired HIV are more likely to start ART with low CD4
counts. Ideally, one would like to compare CD4 cell counts
during virologically suppressive ART with an individual’s
pre–HIV-infection CD4 cell count level, but we did not have
data on pre-HIV infection CD4 cell counts for the individuals
in our study. The level of the ﬁrst postseroconversion CD4
cell count has been shown to be predictive for the CD4 cell
count recovery after the start of ART.35 However, also the
timing of seroconversion and postseroconversion CD4 cell
count were mostly unknown in our data.
The highest CD4 cell counts after 8 years of virologically
suppressive ART were observed for women aged 51–52 years.
Although in women we observed a peak CD4 cell count
response during middle age at all levels of CD4 cell count at
the start, in men, a similar peak was only observed when ART
was started at CD4 counts of 500 cells/mm3, but not at lower
CD4 cell counts. A similar nonlinear age–CD4 response
pattern was found in a recent study.36 Because we did not
observe such a trend in the HIV-negative population, it is not
clear whether an underlying biological process contributes to
our ﬁndings. Adherence to ART has been shown to be less in
younger individuals,37 and differences in compliance may exist
even when all HIV RNA measurements are below the limit of
detection. Poorer adherence may explain the smaller increases
in CD4 cell count after 2–8 years after the start of ART when
ART was started at the age of 20 years compared with middle-
aged men and women. We aimed to select more adherent
individuals in the sensitivity analysis with a stricter deﬁnition
of virologically suppressive ART but results were similar to the
main analysis. The peak in CD4 response in women coincides
with the mean age of natural menopause, but studies have
found no evidence for a difference in CD4 cell count response
after ART initiation between premenopausal and postmeno-
pausal women with a virological response.38,39
A recent study found that CD8 cell count trajectories,
adjusted for baseline CD4 cell count but not for baseline CD8
cell count, were very similar for those starting ART with
a CD4 count of $200 cells/mm3 but long-term CD8 cell
count trajectories were higher with lower baseline CD4 count
when ART was started with counts ,200 cells/mm3.29 We
show that reaching higher long-term CD8 cell counts is not
only associated with lower baseline CD4 cell count but also
with younger age and higher baseline CD8 cell count. CD8
cell counts at 8 years were lower with older age, similar,
albeit at a higher value, compared to the trend in HIV-
negative individuals. The association between higher baseline
CD4 cell counts and lower CD8 cell count trajectories is
counterbalanced by the association between higher baseline
CD8 cell counts. Higher baseline CD8 cell counts usually
accompany higher baseline CD4 cell counts and are associ-
ated with higher CD8 cell count trajectories. Together, this
results in long-term CD8 cell counts that are similar when
ART is started with a CD4 count of 200 cells/mm3 or higher.
Lack of normalization of CD8 cell counts in HIV-positive
individuals was also observed in a recent study by the Danish
HIV Cohort.40 Elevated CD8 cell count levels are suggestive
of ongoing residual immune activation, and residual HIV
viremia, coinfections (such as CMV41), microbial transloca-
tion, loss of immunoregulatory responses, and hypercoagula-
bility are all thought to contribute.42,43
When ART was started at CD4 counts above 200 cells/
mm3 in men and 250 cells/mm3 in women, median CD4 cell
count trajectories reached $500 cells/mm3 within 8 years of
virologically suppressive ART. When ART was started at
a CD4 count of 350 or 500 cells/mm3, median ratios .1 were
reached within 8 years. These cutoffs are frequently used to
identify individuals at increased risk of morbidity and/or
mortality. However, there continues to be an association of
a lower risk of AIDS and death with a higher CD4 cell count,
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even above 500 cells/mm3.44,45 For the CD4:CD8 ratio and
CD8 cell count, these associations are less clear cut. Several
studies have suggested that the CD4:CD8 ratio, independent
of CD4 cell count, predicts time to death and non–AIDS-
deﬁning morbidity.22–24,46 In addition, both low CD8 cell
count in the ﬁrst year after starting ART and increased CD8
cell counts .1500 cells/mm3 at 10 years after the start of
ART have been associated with mortality.40 By contrast,
a recent ART-CC study found only a small effect of CD8 cell
counts and no signiﬁcant effect of the CD4:CD8 ratio on all-
cause mortality.47 It may be that associations between either
CD8 cell count or CD4:CD8 ratio and clinical outcome are
only limited to speciﬁc causes of morbidity or death.
A limitation of our study was that analyses including
data on CD8 cell counts, smoking, and HCV and CMV
coinfection were performed in different subsets of individu-
als, which limits the interpretation of the results because we
did not adjust for all covariates at the same time. Furthermore,
there were few HIV-negative people older than 65 years.
Therefore, comparisons with median HIV-negative values
beyond 65 years are mostly based on extrapolation. Another
limitation is that both HIV-negative cohorts were from
a Western European population, whereas CD4 cell counts
are generally reported to be lower in sub-Saharan African
populations.48 In our study, CD4 and CD8 cell count and
CD4:CD8 ratio trajectories in HIV-positive individuals from
sub-Saharan Africa were all somewhat lower compared with
those from Western Europe or North America. Whether these
differences translate into differential risk of morbidity or
mortality is difﬁcult to investigate because of other socioeco-
nomic and psychosocial differences.
CONCLUSION
Starting ART with a CD4 cell count of$500 cells/mm3
makes reaching a CD4 cell count comparable with those seen
in HIV-negative individuals more likely. However, even
when ART is started with a high CD4 cell count, median
CD4:CD8 ratio trajectories remained below the reference
levels of HIV-negative individuals because of persisting high
CD8 cell counts. To what extent these subnormal immuno-
logical responses affect speciﬁc clinical endpoints requires
further investigation.
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